ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics Statistics
Share Statistics
ProQR Therapeutics has 105.21M shares outstanding. The number of shares has increased by 27.7% in one year.
| Shares Outstanding | 105.21M |
| Shares Change (YoY) | 27.7% |
| Shares Change (QoQ) | 26.35% |
| Owned by Institutions (%) | 54.38% |
| Shares Floating | 70.76M |
| Failed to Deliver (FTD) Shares | 5.18K |
| FTD / Avg. Volume | 1.28% |
Short Selling Information
The latest short interest is 1.01M, so 0.98% of the outstanding shares have been sold short.
| Short Interest | 1.01M |
| Short % of Shares Out | 0.98% |
| Short % of Float | 1.36% |
| Short Ratio (days to cover) | 2.01 |
Valuation Ratios
The PE ratio is -7.53 and the forward PE ratio is -3.7. ProQR Therapeutics's PEG ratio is 2.63.
| PE Ratio | -7.53 |
| Forward PE | -3.7 |
| PS Ratio | 11.05 |
| Forward PS | 1.6 |
| PB Ratio | 2.36 |
| P/FCF Ratio | -5.53 |
| PEG Ratio | 2.63 |
Enterprise Valuation
ProQR Therapeutics N.V. has an Enterprise Value (EV) of 45.84M.
| EV / Earnings | -1.65 |
| EV / Sales | 2.42 |
| EV / EBITDA | -1.9 |
| EV / EBIT | -1.5 |
| EV / FCF | -1.21 |
Financial Position
The company has a current ratio of 3.95, with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.95 |
| Quick Ratio | 3.95 |
| Debt / Equity | 0.19 |
| Total Debt / Capitalization | 16.28 |
| Cash Flow / Debt | -2.11 |
| Interest Coverage | -28.29 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -28.61%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -28.61% |
| Revenue Per Employee | $113,885.54 |
| Profits Per Employee | $-167,246.99 |
| Employee Count | 166 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -197K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -31.09% in the last 52 weeks. The beta is 0.24, so ProQR Therapeutics's price volatility has been higher than the market average.
| Beta | 0.24 |
| 52-Week Price Change | -31.09% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 28.25 |
| Average Volume (20 Days) | 403.79K |
Income Statement
In the last 12 months, ProQR Therapeutics had revenue of 18.91M and earned -27.76M in profits. Earnings per share was -0.34.
| Revenue | 18.91M |
| Gross Profit | 18.91M |
| Operating Income | -30.47M |
| Net Income | -27.76M |
| EBITDA | -24.12M |
| EBIT | -30.47M |
| Earnings Per Share (EPS) | -0.34 |
Balance Sheet
The company has 149.41M in cash and 17.22M in debt, giving a net cash position of 132.19M.
| Cash & Cash Equivalents | 149.41M |
| Total Debt | 17.22M |
| Net Cash | 132.19M |
| Retained Earnings | -427.16M |
| Total Assets | 167.96M |
| Working Capital | 114.94M |
Cash Flow
In the last 12 months, operating cash flow was -36.39M and capital expenditures -1.42M, giving a free cash flow of -37.81M.
| Operating Cash Flow | -36.39M |
| Capital Expenditures | -1.42M |
| Free Cash Flow | -37.81M |
| FCF Per Share | -0.46 |
Margins
Gross margin is 100%, with operating and profit margins of -161.18% and -146.86%.
| Gross Margin | 100% |
| Operating Margin | -161.18% |
| Pretax Margin | -147.9% |
| Profit Margin | -146.86% |
| EBITDA Margin | -127.6% |
| EBIT Margin | -161.18% |
| FCF Margin | -200.01% |
Dividends & Yields
PRQR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -20.73% |
| FCF Yield | -21.98% |
Analyst Forecast
The average price target for PRQR is $9.5, which is 479.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 479.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -1.86 |
| Piotroski F-Score | 3 |